Breaking News Instant updates and real-time market news.

LXRX

Lexicon

$12.81

0.44 (3.56%)

, IPSEY

Ipsen

$33.04

-0.36 (-1.08%)

12:37
09/19/17
09/19
12:37
09/19/17
12:37

Lexicon announces European Commission approves Xermelo

Lexicon Pharmaceuticals (LXRX) announced that the European Commission has approved Xermelo 250 mg as a first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults inadequately controlled by SSA therapy. This approval allows for the marketing of Xermelo by Lexicon's collaborator, Ipsen (IPSEY), in the above indication in all 28 member states of the European Union, Norway and Iceland, the company stated.

LXRX

Lexicon

$12.81

0.44 (3.56%)

IPSEY

Ipsen

$33.04

-0.36 (-1.08%)

  • 25

    Sep

LXRX Lexicon
$12.81

0.44 (3.56%)

03/01/17
WEDB
03/01/17
NO CHANGE
WEDB
Lexicon price target raised to $38 from $33 at Wedbush
Wedbush analyst Liana Moussatos increased her price target on Lexicon after the FDA approved Lexicon's lead drug, Zermelo, for carcinoid syndrome. The analyst thinks that the company has several additional upcoming positive potential catalysts. She keeps an Outperform rating on the stock.
03/07/17
SBSH
03/07/17
NO CHANGE
Target $28
SBSH
Buy
Lexicon price target raised to $28 from $24 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Lexicon Pharmaceuticals to $28 saying the company's potential in diabetes remains underappreciated. Management's commentary on sotagliflozin should re-assure investors who remain unconvinced about the T1D thesis, Nochomovitz tells investors in a post-earnings research note. He keeps a Buy rating on Lexicon.
09/13/17
JPMS
09/13/17
NO CHANGE
JPMS
Neutral
Editorial published with Lexicon data reads cautiously, says JPMorgan
JPMorgan analyst Jessica Fye noted that full results for Lexicon Pharmaceuticals' Phase 3 inTandem3 study were released in the New England Journal of Medicine, accompanied by an editorial that reads cautiously on associated diabetic ketoacidosis. The comments from the editorial give her further pause on overall DKA risk and she thinks the relative risk in pumps patients may be at a threshold where physicians and the FDA could be cautious, she tells investors. Fye keeps a Neutral rating on Lexicon shares, which have fallen by more than 9% following the publication.
09/15/17
SBSH
09/15/17
NO CHANGE
Target $28
SBSH
Buy
Lexicon sold off on increased competition concerns, says Citi
Citi analyst Yigal Nochomovitz attributes the 10% selloff yesterday in shares of Lexicon Pharmaceuticals to increased competition after the 24-week results from the Depict1 trial for dapagliflozin in type 1 diabetes were presented. The data are broadly in line with what we've seen from sotagliflozin, suggesting a similar efficacy and safety profile between the two drugs, Nochomovitz tells investors in a research note. He reminds investors that he always expected competition in the adjunctive type 1 diabetes space, and currently models 35% peak share for sotagliflozin, which he thinks leaves "plenty of room for another SGLT inhibitor." The analyst has a Buy rating on Lexicon with a $35 price target.
IPSEY Ipsen
$33.04

-0.36 (-1.08%)

09/19/17
SOCG
09/19/17
UPGRADE
SOCG
Buy
Ipsen upgraded to Buy from Hold at Societe Generale
Societe Generale analyst Delphine Le Louet upgraded Ipsen to Buy with a price target of EUR 126.

TODAY'S FREE FLY STORIES

T

AT&T

$33.98

0.07 (0.21%)

, ATUS

Altice USA

$18.69

0.07 (0.38%)

12:36
09/25/18
09/25
12:36
09/25/18
12:36
Hot Stocks
AT&T launches new advertising company called Xandr »

AT&T (T) announced…

T

AT&T

$33.98

0.07 (0.21%)

ATUS

Altice USA

$18.69

0.07 (0.38%)

FTR

Frontier Communications

$6.49

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 21

    Oct

  • 24

    Oct

  • 06

    Nov

  • 12

    Nov

SQ

Square

$92.04

5.975 (6.94%)

12:34
09/25/18
09/25
12:34
09/25/18
12:34
Hot Stocks
Square introduces new payroll app for employers »

Square said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 26

    Nov

ULTA

Ulta Beauty

$277.98

-3.03 (-1.08%)

12:32
09/25/18
09/25
12:32
09/25/18
12:32
Conference/Events
Cowen retail/luxury analyst to hold an analyst/industry conference call »

Retail/Luxury Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

ILIAF

Iliad

$0.00

(0.00%)

12:30
09/25/18
09/25
12:30
09/25/18
12:30
Downgrade
Iliad rating change  »

Iliad downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXP

Eagle Materials

$86.54

0.08 (0.09%)

12:27
09/25/18
09/25
12:27
09/25/18
12:27
Periodicals
Breaking Periodicals news story on Eagle Materials »

Hedgeye adds Eagle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 06

    Nov

EA

Electronic Arts

$115.78

0.52 (0.45%)

, MSFT

Microsoft

$114.29

-0.43 (-0.37%)

12:26
09/25/18
09/25
12:26
09/25/18
12:26
Hot Stocks
Game On: Sony launching PlayStation Classic in December »

Welcome to "Game…

EA

Electronic Arts

$115.78

0.52 (0.45%)

MSFT

Microsoft

$114.29

-0.43 (-0.37%)

SNE

Sony

$58.61

1.75 (3.08%)

NTDOY

Nintendo

$0.00

(0.00%)

SGAMY

Sega Sammy Holdings

$0.00

(0.00%)

CCOEY

Capcom

$0.00

(0.00%)

UBSFY

Ubisoft

$0.00

(0.00%)

TTWO

Take-Two

$135.22

0.35 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 21

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 13

    Nov

  • 28

    Nov

  • 03

    Mar

DDD

3D Systems

$20.19

1 (5.21%)

12:25
09/25/18
09/25
12:25
09/25/18
12:25
Options
3D Systems call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

MDWD

MediWound

$6.45

(0.00%)

12:23
09/25/18
09/25
12:23
09/25/18
12:23
Recommendations
MediWound analyst commentary  »

MediWound BARDA contract…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

KORS

Michael Kors

$67.12

0.41 (0.61%)

, SONC

Sonic

$43.31

6.7 (18.30%)

12:22
09/25/18
09/25
12:22
09/25/18
12:22
General news
Fly Intel: Wall Street's top stories at midday »

Stocks opened in positive…

KORS

Michael Kors

$67.12

0.41 (0.61%)

SONC

Sonic

$43.31

6.7 (18.30%)

BMWYY

BMW

$0.00

(0.00%)

F

Ford

$9.49

-0.1 (-1.04%)

GM

General Motors

$34.00

-0.74 (-2.13%)

FCAU

Fiat Chrysler

$18.10

-0.21 (-1.15%)

XOXO

XO Group

$34.75

7.13 (25.81%)

ASNA

Ascena Retail

$4.46

0.44 (10.95%)

TGTX

TG Therapeutics

$5.98

-3.275 (-35.41%)

CTL

CenturyLink

$21.13

-1.77 (-7.73%)

TMUS

T-Mobile

$69.28

0.35 (0.51%)

S

Sprint

$6.42

0.03 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 01

    Oct

  • 02

    Oct

  • 04

    Oct

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
09/25/18
09/25
12:17
09/25/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
09/25/18
09/25
12:16
09/25/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
09/25/18
09/25
12:15
09/25/18
12:15
General news
Treasury Option Action: another round of put buying »

Treasury Option Action:…

THR

Thermon Group

$26.12

0.14 (0.54%)

12:15
09/25/18
09/25
12:15
09/25/18
12:15
Conference/Events
Thermon Group management to meet with William Blair »

Group luncheon with CFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

12:10
09/25/18
09/25
12:10
09/25/18
12:10
General news
Treasury 5-year auction outlook: the $38 B 5-year sale may not do much better »

Treasury 5-year auction…

I

Intelsat

$26.03

3.32 (14.62%)

12:05
09/25/18
09/25
12:05
09/25/18
12:05
Options
Intelsat call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$11.45

-0.295 (-2.51%)

, EXC

Exelon

$42.67

-0.54 (-1.25%)

12:04
09/25/18
09/25
12:04
09/25/18
12:04
Periodicals
GE turbine at EDF's Bouchain plant halted following U.S. shutdowns, Reuters says »

A General Electric (GE)…

GE

General Electric

$11.45

-0.295 (-2.51%)

EXC

Exelon

$42.67

-0.54 (-1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 11

    Nov

SAN

Banco Santander

$5.29

0.015 (0.28%)

, UBS

UBS

$16.47

0.075 (0.46%)

12:03
09/25/18
09/25
12:03
09/25/18
12:03
Hot Stocks
Banco Santander appoints Andrea Orcel as new CEO »

Banco Santander (SAN)…

SAN

Banco Santander

$5.29

0.015 (0.28%)

UBS

UBS

$16.47

0.075 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ORCL

Oracle

$51.82

0.57 (1.11%)

11:57
09/25/18
09/25
11:57
09/25/18
11:57
Hot Stocks
S&P revises Oracle outlook to Negative on higher share repurchases »

S&P Global Ratings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

11:55
09/25/18
09/25
11:55
09/25/18
11:55
General news
Treasury's $17 B 2-year FRN reopening was awarded at a high discount margin of 0.050% »

Treasury's $17 B…

11:55
09/25/18
09/25
11:55
09/25/18
11:55
Conference/Events
Stephens retail/broadlines analyst to hold a luncheon meeting »

Specialty Pharmaceuticals…

11:55
09/25/18
09/25
11:55
09/25/18
11:55
Conference/Events
Stephens real estate services analyst to hold group luncheon »

Real Estate Services…

11:55
09/25/18
09/25
11:55
09/25/18
11:55
Conference/Events
RBC Capital internet analyst to hold a luncheon »

Internet Analyst Mahaney…

SAGE

Sage Therapeutics

$140.90

-1.71 (-1.20%)

11:53
09/25/18
09/25
11:53
09/25/18
11:53
Hot Stocks
Sage depression drug to get FDA panel review on Nov. 2 »

The FDA earlier today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

DNKN

Dunkin' Brands

$73.41

0.53 (0.73%)

11:52
09/25/18
09/25
11:52
09/25/18
11:52
Hot Stocks
Dunkin' Brands to officially rebrands 'Dunkin Donuts' as just 'Dunkin' »

Dunkin' Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$150.89

-0.67 (-0.44%)

11:51
09/25/18
09/25
11:51
09/25/18
11:51
Conference/Events
Deere management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.